Effects of Tamoxifen and Prednisolone on Breast Cancer Enzymes
Author Information
Author(s): N. Deshpande, I. Mitchell, I M. Maltinti, A. Boi, L. Di Martino
Primary Institution: Imperial Cancer Research Fund
Hypothesis
The beneficial effects of tamoxifen or prednisolone in prolonging the relapse-free interval might be mediated via alterations in the activity of a-GPDH in micrometastases.
Conclusion
Tamoxifen and prednisolone treatment can alter the activity of certain enzymes in breast cancer, potentially affecting the growth of the carcinoma.
Supporting Evidence
- Tamoxifen treatment resulted in a significant increase in the activity of a-GPDH.
- Ethynyl-oestradiol treatment produced a significant decrease in the activity of a-GPDH.
- Prednisolone treatment resulted in a significant increase in the activity of a-GPDH.
Takeaway
This study looked at how two drugs, tamoxifen and prednisolone, change the way certain enzymes work in breast cancer, which might help doctors understand how to keep cancer from coming back.
Methodology
Postmenopausal women with breast cancer were treated with tamoxifen, ethynyl-oestradiol, or prednisolone for up to 12 days before mastectomy, and enzyme activities were measured.
Limitations
The study only included postmenopausal women and the sample size was limited.
Participant Demographics
Postmenopausal women aged 57-76 with confirmed breast carcinoma.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website